The randomized, double-blind, placebo-controlled, REACH-2 phase III clinical trial aimed to establish the efficacy of ramucirumab, a humanized monoclonal antibody directed against VEGF 2, in patients with advanced HCC, disease progression following first-line sorafenib therapy, and alpha-fetoprotein concentrations of 400 ng/mL or higher. This evidence concerns the gene AFP and hepatocellular carcinoma.